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 Abstract  
 
The gastrointestinal (GI) tract plays an important role in the absorption of orally administered drugs. 
However, in some cases the anatomy of the GI tract is changed due to GI surgery, which has the 
potential of influencing drug bioavailability. In this review, we aim to compile, review, and comment 
the existing but sometimes fragmented scientific data regarding the impact of GI surgery on the oral 
bioavailability of drugs.  Relevant reports were gathered through the PubMed database from 
database inception through January 2012. Drugs for which at least one trial or case report suggested 
a change in oral bioavailability or absorption caused by GI surgery are discussed in detail. Major 
methodological differences, such as study design, number of subjects and choice of reference group, 
were observed in the reported studies. Predicting the impact of GI surgery on the oral bioavailability 
was therefore difficult to perform, even the most sophisticated classification systems could not be 
used for predicting purposes.
 1. INTRODUCTION 
 
During drug development, the oral bioavailability of a drug is usually studied in healthy volunteers 
and in patients with a normal gastrointestinal (GI) tract. However, once the drug is commercially 
available, it may also be administered to patients with an anatomically changed GI tract. Changing 
the anatomy of the GI tract is often the consequence, or even the goal, of surgical treatment options 
in GI diseases such as GI cancer or morbid obesity. However, irreversible anatomical changes may 
affect various factors contributing to the bioavailability of oral drugs (e.g. gastric and intestinal pH, 
the surface area available for absorption, active transport mechanisms for absorption). In the past 40 
years, drug bioavailability after GI surgery has been extensively studied in humans. However, the 
existing data are scattered and sometimes fragmented or limited due to case reports and small 
clinical trials. In this paper, these data were summarized, reviewed and commented in order to make 
an attempt to (1) predict the impact of an anatomically changed GI tract on the oral bioavailability of 
specific drugs and to (2) judge whether dose adjustments are needed in these specific patient 
populations. 
We therefore performed a systematical literature search on the impact of surgical changes in the 
anatomy of the GI tract on the bioavailability of oral drugs. The absorption of oral drugs may also be 
affected by surgery in general, because of e.g. fluctuating haemodynamics, physiological shifts, 
intense metabolic changes, reduced GI motility. However, these temporary influences have 
been well described elsewhere 1 and fall outside the scope of this review. Also the technical aspects 
of drug administration procedures in, for example, patients with feeding tubes have been described 
in detail elsewhere 2,3 and are not part of this review. The main focus in this systematical review will 
therefore be the long-term influences of an anatomically changed GI tract due to GI surgery. 
 
2. DATA SELECTION 
 
We searched the PubMed database for literature examining the impact of an anatomically 
changed GI tract on drug bioavailability from database inception through January 2012. 
Additional references were hand searched from the reference lists of identified articles or 
relevant reviews. The search was limited to English language articles. This paper discusses 
both case reports and controlled trials. The studies used for this review were selected from a 
pharmacokinetic point of view: the primary outcome was absorption or bioavailability. Since 
the impact on absorption and on bioavailability are different outcomes, two study designs are 
possible. The oral administration of a drug after the GI tract has been anatomically changed 
can be compared either to the intravenous administration after GI surgery, or to the oral 
administration in subjects with a normal GI tract; thereby investigating the impact on 
absorption and bioavailability, respectively. Articles evaluating only efficacy or safety were 
excluded. 
 3. GI SURGICAL PROCEDURES AND THEIR INFLUENCE ON THE DRUG 
ABSORPTION PROCESS 
 
In order to assess the influence of anatomical changes in the GI tract on oral bioavailability, it is 
essential to understand the fundamental concepts of oral bioavailability and its contributing factors. 
The following briefly reflects on some of these fundamentals. 
The term “oral bioavailability” is used to indicate the fractional extent to which a dose of drug 
reaches its site of action or a biological fluid from which the drug has access to its site of action.4 
Because measuring drug concentration at its site of action is complicated in human subjects, most 
bioavailability studies determine the systemic exposure to the unchanged drug by measuring plasma 
or serum concentrations of the drug. These concentrations are used to construct a concentration-
time curve and systemic exposure is expressed as the area under the concentration-time curve 
(AUC). Although this parameter is affected by all the pharmacokinetic processes (absorption, 
distribution, metabolism and elimination), one would expect mainly altered absorption to be 
responsible for alterations in the AUC after an anatomical change in the GI tract. 
The absorption of oral drugs from the GI tract into the systemic circulation is a complex process. The 
rate (expressed as time to reach maximum concentration, tmax) and the extent of absorption depend 
on several factors. The physical state of the drug (solution, suspension or solid dosage form) is the 
first factor that affects the drug absorption process.  Drugs given in aqueous solution are more 
rapidly absorbed than those given in oily solution, suspension or solid form.5,6 The latter requires 
disintegration in order to become soluble within the GI environment. This step is promoted by gastric 
mixing and is often the rate-limiting step in the absorption process. Subsequently, the dissolution of 
the drug is determined by its water solubility. Lipophilic drugs may therefore need bile acids to 
enhance their solubility. Also gastric and intestinal pH are important factors influencing ionization 
and, consequently, drug solubility. The last step in the absorption process is the diffusion of the drug 
across the GI membranes in order to become available into the systemic circulation. Most drugs are 
absorbed from the GI tract by passive diffusion favoring the absorption of unionized, lipophilic drugs. 
Other drugs may require transporters for their absorption. Not only membrane permeability, but also 
site of absorption, surface area available for absorption, drug concentration and blood flow at the 
site of absorption and contact time with the GI tract (gastric emptying time and intestinal transit 
time) are important factors influencing the rate and extent of absorption.4 Most drugs are absorbed 
in the proximal small intestine (duodenum and jejunum) because of its large surface area created by 
the microvilli, its generous blood flow and its permeable mucosa.5,7 Nevertheless, absorption from 
other parts of the GI tract is also possible: some weak acids, unionized drugs and lipophilic 
substances may already be absorbed from the stomach.8  
During or following absorption from the GI tract, the drug can be metabolized by GI or hepatic 
enzymes, before it reaches the systemic circulation; this is called first pass metabolism. In addition, 
some drugs are substrates for P-glycoprotein (P-gp) which hampers absorption by pumping the drug 
back into the GI tract. All of this is the phenomenon of presystemic elimination. Drugs with a high 
presystemic elimination consequently have a low systemic exposure and bioavailability. 
 GI surgical procedures often cause irreversible alterations to the anatomy of the GI tract which may 
have an impact on the absorption and/or bioavailability of oral drugs.  
Taking the several steps of the absorption process of oral drugs into account, changes in (1) GI pH, (2) 
gastric emptying, (3) intestinal transit time, (4) surface area for absorption and (5) first pass 
metabolism capacity, are assumed to affect the rate and/or the extent of absorption of oral drugs 
[6]. In addition, the elimination of drugs (e.g. enterohepatic recirculation) could also be influenced by 
GI surgery.9-11 Because both elimination and absorption contribute to the systemic exposure to a 
drug, changes to one of these processes will obviously alter the bioavailability of a drug. Table 1 
summarizes the GI surgical procedures and their possible effects on the bioavailability of oral drugs. 
 
4. ORAL BIOAVAILABILITY OF DRUGS IN PATIENTS WITH AN ANATOMICALLY 
CHANGED GI TRACT 
Table 2 summarizes the selected controlled studies and case reports that have described the impact 
of an anatomically changed GI tract on the absorption and/or bioavailability of oral drugs. Even 
though Table 2 gives a complete overview, in the following sections we only focus on those drugs for 
which at least one trial or case report suggested a change in oral bioavailability or absorption caused 
by GI surgery.  
 
4.1. Analgesics 
The most important absorption site of paracetamol has been suggested to be the jejunum distal to 
the duodenojejunal flexure.17  This implies that bypassing or removing this part of the jejunum could 
result in malabsorption of paracetamol after oral administration and consequently in a reduced 
bioavailability. In fact, AUC values observed after oral administration in patients with a 
duodenostomy or a jejunostomy (ranging from 15 cm to 60 cm distal from the duodenojejunal 
flexure) (n = 5) were significantly lower compared to those observed in healthy volunteers with a 
normal GI tract (n = 32).17 In addition, pylorus preserving pancreatoduodenectomy (PPPD) (n= 12) 
and jejunoileal bypass (JIB) (n = 3) (both preserving the duodenojenunal flexure) had no impact on 
the bioavailability of oral paracetamol.17,19  Even administration of paracetamol as an oral elixir 
through a jenunostomy tube (n = 2) resulted in similar pharmacokinetic parameters as in healthy 
volunteers with a normal GI tract (n = 4).20  
The rate of absorption of paracetamol appears to depend on gastric emptying time.64 Partial (n = 7) 
and total gastrectomies (n = 5) accelerate gastric emptying, resulting in a shorter tmax and a higher 
Cmax for oral paracetamol. Although it is more rapidly absorbed from the GI tract, gastrectomy has no 
clinically relevant impact on the systemic exposure to paracetamol since AUC values were similar to 
those in healthy volunteers with a normal GI tract (n = 32).17 
 
4.2. Cardiovascular drugs 
4.2.1. Digoxin 
Absorption of oral digoxin primarily occurs in the proximal small intestine (i.e. duodenum and 
jejunum) 5, and resections of various amounts of the ileum (n = 14) demonstrated to have no impact 
on the bioavailability of digoxin compared to that in healthy volunteers with a normal GI tract (n = 
16).24 Additionally, JIB surgery, which bypasses a part of the jejunum and ileum, does not necessarily 
affect the bioavailability of digoxin; the length of the remaining jejunum and the preservation of 
intestinal continuity with the large intestine seemed to play a major role in the absorption process. 
The lack of intestinal continuity due to an end-jejunostomy appears to result in ineffective serum 
levels in 1 patient.26 Furthermore, Marcus et al. 23 reported no significant differences in AUC values 
before and after JIB surgery with 300mm of jejunum left (n = 7), whereas in a study of Gerson et al. 24 
a reduced bioavailability of digoxin was observed in 5 of 9 patients with JIB compared to healthy 
subjects with a normal GI tract (n = 16). Those patients with the most decreased AUC values had only 
250 to 263 mm of jejunum left after JIB surgery. In fact, Gerson et al. 24 found a strong correlation 
between the length of the remaining jejunum and the bioavailability of digoxin. A reduced 
bioavailability however may still result in therapeutic levels of digoxin.25,65 Nevertheless, since digoxin 
has a small therapeutic range 66, therapeutic drug monitoring of digoxin may be recommended in 
patients with an anatomically changed GI tract. 
4.2.2. Quinidine 
It would be expected that an increased gastric pH results in a reduced ionization of the basic drug 
quinidine and, consequently, in a better absorption due to a larger fraction unionized quinidine. In 
contrast, in patients with gastrectomy combined with vagotomy (n = 10), the serum quinidine levels 
were significantly reduced at all times of observation during the 6-hour experiment compared to the 
levels obtained before surgery.27 However, it should be mentioned that the postoperative serum 
levels were still rising at 6 hours postdose, while preoperative serum levels reached a maximum at 2 
– 4 hours postdose. Therefore, it can only be concluded that the rate of absorption of quinidine is 
reduced after gastrectomy with vagotomy.27 In the same study, no differences were found in the 
serum levels pre- and postoperatively in patients with only partial gastrectomy (n = 2).27 Due to these 
limited data, it is difficult to predict the impact of GI surgery on the bioavailability of oral quinidine. 
4.2.3. Atenolol and propranolol 
Like quinidine, a better absorption after an increase of gastric pH could theoretically be expected for 
the basic drugs atenolol (pKa 9.6) and propranolol (pKa 9.5). However, the rate of absorption 
(expressed as tmax) and the systemic exposure to atenolol (expressed as AUC) in patients with partial 
gastrectomy (n = 29) were comparable to those of healthy control subjects (n = 18), indicating that 
partial gastrectomy had no impact on the bioavailability of oral atenolol.14 
Theoretically, the absorption of propranolol should also be improved due to an increase in gastric pH; 
however, the opposite was observed in patients with partial gastrectomy. In contrast to atenolol, 
systemic exposure to propranolol in these patients (n = 29) was significantly lower compared to that 
in healthy subjects with a normal GI tract (n = 18).14 The observed difference in impact of partial 
gastrectomy on the bioavailability of atenolol and propranolol was suggested to be due to their 
different physicochemical properties, atenolol being hydrophilic and propranolol lipophilic). Leth et 
al. 67 observed a 70% reduction in excretory pancreatic function after partial gastrectomy and a 
subsequent reduction of lipid absorption. The authors 14 hypothesized that this observation was in 
line with the reduced absorption of the more lipophilic propranolol. In contrast, partial gastrectomy 
combined with vagotomy (n = 4) did not reduce the systemic exposure to propranolol; systemic 
exposures were even similar to those obtained before surgery.13 In addition, patients with only 
vagotomy (n = 7) also had a comparable systemic exposure to that before surgery.13 Although 
systemic exposure was not altered in both these patients groups, the rate of absorption differed 
between these groups. The absorption was significantly slower after vagotomy compared to that 
before surgery, whereas the rate of absorption remained normal in patients after vagotomy 
combined with partial gastrectomy.13 Delayed gastric emptying, as a result of vagotomy, was 
probably compensated by the impact of partial gastrectomy on gastric emptying time. 
In conclusion, these studies 13,14 are not consistent and several factors such as lipophilicity and gastric 
emptying time seem to influence the absorption of propranolol. 
4.2.4. Hydrochlorothiazide 
Despite an intact duodenum and upper jejunum (the major site of absorption of 
hydrochlorothiazide), a 50% decrease in systemic exposure to hydrochlorothiazide was observed in 5 
patients after JIB surgery 28 when compared to previously reported AUC values of 8 healthy subjects 
with a normal GI tract. The investigators suggested that absorption of the drug occurred almost 
normally but that the time period for absorption was not long enough due to a shorter intestinal 
transit time. These findings should be interpreted with caution since the AUC values used as a 
reference for subjects with normal GI tract were obtained by another group of investigators and 
group characteristics were not matched (e.g. different mean bodyweight and different number of 
subjects). 
4.2.5. Atorvastatin 
Atorvastatin has a variable and complex intestinal and hepatic first pass metabolism. It is not only 
metabolized enzymatically by CYP3A4 and CYP3A5, whose expression is highest in the duodenum, 
but it is also a substrate for P-glycoprotein. Bypassing a large part of the small intestine, and 
particularly the duodenum, may therefore result in an altered bioavailability of atorvastatin. In fact, 
both biliopancreatic diversion (BPD) with duodenal switch (n = 10) 30 and gastric bypass (n = 12) 29 
had a variable but significant impact on the systemic exposure to atorvastatin. This impact showed to 
be associated with the presurgical first pass metabolism capacity of the GI tract. Nine patients with a 
high first pass metabolism of atorvastatin and consequently a low systemic exposure prior to surgery 
showed a median 1.2-fold increase in systemic exposure to atorvastatin after gastric bypass surgery, 
whereas in 3 other patients with a low first pass metabolism before surgery, a median 2.6-fold 
reduced systemic exposure was observed compared to that before surgery.29 Because the anatomy 
of the GI tract after BPD with duodenal switch has been changed more drastically, the impact of this 
surgical procedure on the bioavailability of atorvastatin is even more apparent than after gastric 
bypass surgery. Here, a significant mean 2-fold higher systemic exposure to atorvastatin was 
observed after BPD with duodenal switch compared to that before surgery.30 As a consequence, 
lower effective doses of atorvastatin should be used in these patients. 
 
4.3 Drugs for the central nervous system 
For phenytoin, a high interindividual variability in its pharmacokinetics and a narrow therapeutic 
range have been described.68 Therefore, caution is recommended when phenytoin is administered 
orally in patients with an anatomically changed GI tract. In a controlled study, the bioavailability of 
phenytoin was proven to be significantly reduced after JIB surgery (n = 7) compared to control 
subjects with a normal GI tract (n = 9).33 Peterson and Zweig moreover reported a patient who had 
recurrent seizures several weeks after JIB surgery and who also required higher doses of phenytoin 
and ethosuximide to maintain successful therapy.34 Although no controlled study evaluated the 
influence of gastric bypass on the bioavailability of oral phenytoin, one case was reported of a 
patient with undetectable phenytoin levels after gastric bypass surgery despite the administration of 
high doses.35 Therefore, patients with an anatomically changed GI tract should be carefully 
monitored when phenytoin is given orally. Even intravenous administration might be considered. 
 
4.4 Hormones and related compounds 
4.4.1 Metformin 
It was hypothesized that bypassing the major absorption site of metformin (i.e. duodenum and 
jejunum) would reduce its oral bioavailability. In contrast, a trend towards increased metformin 
absorption and bioavailability was observed in 16 nondiabetic post-gastric bypass patients compared 
to 16 healthy controls.37 The investigators suggested several factors that could explain the increased 
systemic exposure to metformine after gastric bypass surgery. Metformin absorption is transporter 
dependent and saturable. Preventing saturation of these transporters by decreasing the rate at 
which the drug enters the small intestine (e.g. delayed gastric emptying because of gastric bypass 
surgery) could therefore result in a higher systemic exposure. Also upregulation of these transporters 
may occur after changing the anatomy of the GI tract. Consequently, decreasing the surface area for 
absorption does not necessarily reduce the bioavailability of drugs. 
4.4.2 Thyroxine 
One case report described inadequate therapeutic levels after JIB surgery and 3-fold higher doses 
were needed in this patient for the treatment of hypothyroidism 39,69; but no controlled studies are 
available that describe the impact of an anatomically changed GI tract on the absorption or 
bioavailability of the thyroid hormone thyroxine. 
4.4.3 Oral contraceptives 
Fertility is often improved by weight loss after bariatric surgery.70 Furthermore, due to the possible 
nutritional deficiencies caused by bariatric surgery, pregnancy should be avoided during the rapid 
weight loss period, that is for at least 1 year after surgery.70,71 It is therefore important to know 
whether an anatomically changed GI tract may affect the bioavailability of oral contraceptives. 
Only 2 controlled studies evaluated the impact of JIB surgery on the pharmacokinetics of oral 
contraceptives.40,41 Victor et al. 41 reported lower plasma levels of norethisterone and levonorgestrel 
in patients with JIB (n = 6). However, this decrease was only statistically significant for levonorgestrel 
during the absorptive phase (at 2, 4 and 6h after administration) compared to the levels of 5 healthy 
non-obese women with a normal GI tract.41 Andersen et al. 40 found no evidence for malabsorption 
of levonorgestrel, oestradiol and oestrone after JIB surgery (n = 12). On the contrary, in this study 
levonorgestrel levels were significantly higher after JIB surgery compared to those of morbidly obese 
women before surgery (n = 6). According to Andersen et al. 40, there is a reasonable explanation for 
this increase in plasma levels of levonorgestrel after surgery. They found a significant negative 
correlation between peak levels and body weight suggesting that obesity, and not intestinal bypass, 
may affect the levonorgestrel levels. Women had low levonorgestrel levels because of obesity, but 
after major weight loss due to JIB surgery, levonorgestel levels were increased. This hypothesis 
however was not confirmed by a pharmacokinetic study of Westhoff et al.72 They evaluated the 
systemic exposure and peak levels of ethinyl oestradiol and levonorgestrel in obese women and 
compared the values with those of healthy normal-weight controls. Here, the differences in systemic 
exposure and peak levels were not statistically significant for levonorgestrel, while a significant lower 
systemic exposure and lower peak levels of ethinyl oestradiol were observed in the obese women 
compared to the normal-weight controls. This, again, indicates the influence of a control group on 
the interpretation of the results. Both studies 40,41 included women with a normal GI tract as control 
group, but the mean bodyweight of the both control groups differed substantially. The control group 
of Andersen et al. consisted of morbidly obese women who were studied before JIB surgery, whereas 
Victor et al. used non-obese women as a reference group. Taking these 2 studies into account, a 
negative impact of JIB surgery on the bioavailability of oral contraceptives can not be excluded. 
The absorption of oral levonorgestrel has also been evaluated in patients with an end-ileostomy. 
Nilsson et al. 16 reported slightly lower levonorgestrel levels in patients who had undergone 
proctocolectomy with a conventional ileostomy (n = 5), while patients with a continent ileostomy 
reservoir (n = 10) achieved significantly lower levels compared to those of healthy control subjects (n 
= 5 and n = 4, respectively).16 The lack of a colon and consequently the lack of normal bacterial flora 
could be responsible for the observed decrease in absorption since the absorption of levonorgestrel 
is influenced by bacteria. Additionally, the absolute bioavailability of levonorgestrel and 
ethinyloestradiol in patients with an end-ileostomy was investigated by Grimmer et al.15 After 
intravenous administration of levonorgestrel, a significantly higher AUC was observed in patients 
with an ileostomy (n = 5) compared to healthy controls (n = 5). The opposite was found for 
intravenous ethinyloestradiol for which the AUC was significantly lower in patients with an ileostomy. 
The same trends were seen after oral administration. Nevertheless, the absolute bioavailability in 
patients with an ileostomy was comparable to that in the healthy control subjects. The authors found 
no apparent explanation for this phenomenon. Unlike levonorgestrel, ethinyloestradiol exhibits 
enterohepatic recirculation which requires the presence of bacterial flora. One could hypothesize 
that, due to the lack of a colon in patients with an ileostomy, part of the drug cannot be reabsorbed 
resulting in a lower AUC. 
In conclusion, evidence regarding a reduced bioavailability of oral contraceptives is quite limited in 
patients with an anatomically changed GI tract. Furthermore, none of the observed lower plasma 
levels of oral contraceptives after GI surgery were below the minimal level required to ensure 
ovulation inhibition. Some of these lower plasma levels were even comparable to those found in 
healthy women taking lower-dose pills.  Consequently, a good efficacy could be achieved with the 
normal-dose pills even if the systemic exposure to oral contraceptives is reduced due to GI surgery. 
Nevertheless, it seems advisable to avoid lower-dose pills in patients with an anatomically changed 
GI tract. Information regarding evidence on the safety and efficacy of oral contraceptives in women 
who had undergone bariatric surgery for obesity can be found in a systemic review of Paulen et al.70 
 
4.5 Immunosuppressants  
4.5.1 Sirolimus, tacrolimus and mycophenolic acid 
According to a study of Rogers et al. 42, the systemic exposure to sirolimus (n = 4), tacrolimus (n = 5) 
and mycophenolic acid (n = 5) tends to be reduced after gastric bypass surgery compared to patients 
with a normal GI tract, but a statistical test was not performed. Although their results have been 
dose-normalized, it should be emphasized that these results were compared to previously published 
exposure data in the non-bypass population using different doses and formulation forms, suggesting 
that the control group used may be unsuitable for comparison. Nevertheless, because of the narrow 
therapeutic range and interindividual variability in blood concentrations, therapeutic monitoring is 
required and the risk of a reduced bioavailability after GI surgery should be kept in mind. 
4.5.2 Cyclosporine  
Because bile enhances the absorption of cyclosporine 73, GI surgical procedures that affect bile 
secretions (e.g. gastric bypass) are likely to influence the bioavailability of cyclosporine. This 
hypothesis has been confirmed by Marterre et al. 43; in order to maintain similar trough cyclosporine 
levels, higher doses of cyclosporine were required in 3 patients after gastric bypass compared to 
those before surgery.43 Reduced cyclosporine levels were also observed in 2 patients after JIB.44,45 
 
4.6 Antimicrobial – antiviral drugs 
4.6.1 Moxifloxacin  
The absorption of oral moxifloxacin was not affected in 12 patients who had undergone gastric 
bypass surgery 46: the exposure to moxifloxacin was found to be equivalent for oral and intravenous 
administration after gastric bypass surgery, indicating that the absolute bioavailability is similar to 
that in subjects with a normal GI tract. However, these exposure data seemed to be higher for both 
administration routes compared to previously published data in healthy volunteers without a gastric 
bypass. This suggests that the elimination phase (e.g. enterohepatic recirculation) is likely to be 
affected by the anatomical changes in the GI tract. Nevertheless, this study was not designed to 
provide insight into the other pharmacokinetic processes and therefore, statistical confirmation of a 
changed elimination was not possible. 
4.6.2. Sulfafurazole and sulfamethazine 
Since sulfafurazole is an acidic sulfonamide, a reduced absorption was suggested after GI surgical 
procedures that increase gastric pH. Despite the fact that sulfafurazole serum levels were decreased 
in patients with a gastrectomy combined with vagotomy (n = 10), patients with only partial 
gastrectomy (n = 2) unexpectedly achieved similar levels as before surgery.27 Like quinidine 
(described in section 4.2.2), the postoperative serum levels in patients with gastrectomy combined 
with vagotomy were also still rising at 6 hours postdose, while preoperative serum levels reached a 
maximum at 2 – 4 hours postdose. The absorption phase of sulfafurazole therefore seems to be 
prolonged in patients with gastrectomy combined with vagotomy. Similarly, the absorption of 
sulfamethazine (also an acidic sulfonamide) was delayed (but not reduced) in patients with 
gastrectomy combined with vagotomy (n = 4).12 The absorption in patients with only vagotomy (n = 
4) however was not impaired.12 Taking these studies into account, changes in absorption are more 
likely attributed to the association of vagotomy with partial gastrectomy. In addition, JIB surgery had 
no impact on the oral bioavailability of sulfafurazole.47 
4.6.3. Penicillin 
Penicillin exhibits a large first pass metabolism. Reducing this first pass metabolic capacity by 
bypassing a large part of the small intestine will definitely increase the bioavailability of oral 
penicillin. In fact, higher AUC values were achieved after JIB surgery (n = 3) compared to those before 
surgery.19 
4.6.4. Ethambutol, isoniazid and rifampicin 
The bioavailability data of the antituberculosis agents ethambutol, isoniazid and rifampicin after GI 
surgery are rather fragmented and limited to case reports of patients after JIB surgery. Although 
therapeutic levels of ethambutol and isoniazid were achieved in most patients 48-52, rifampicin levels 
were lower after JIB 49,50,52. Only one patient was reported to have lower ethambutol levels.50 These 
observations, however, were never confirmed by a controlled study in patients with JIB. The 
absorption of oral ethambutol has also been described in patients with vagotomy and partial 
gastrectomy.27 The latter (n = 2) did not modify the absorption, whereas malabsorption was found in 
patients with vagotomy in combination with partial gastrectomy (n = 10).  
4.6.5. Lopinavir  
The serum/plasma levels of lopinavir have been studied in 2 different patients with an anatomically 
changed GI tract. One patient with total gastrectomy achieved lopinavir levels that were comparable 
to previously reported effective levels.53 Moreover, Kamimura et al. 54 reported a patient with a 
percutaneous jejunal tube due to duodenal stenosis. Lopinavir was consequently administered 
through this jejunostomy tube, but ineffective concentrations of lopinavir were obtained. In contrast, 
removing the jejunostomy tube and performing a gastrojejunal bypass resulted in effective serum 
levels. This surgical procedure preserved a larger part of the jejunum which appeared to be an 
important absorption site for lopinavir. 
4.6.6. Acyclovir  
Although no controlled studies were performed to evaluate the impact of GI surgery on the 
bioavailability of oral acyclovir, there is one case report that showed reduced plasma levels of 
acyclovir after oral administration in a patient with terminal ileal resection.55 
 
4.7. Antitumoral drugs 
Patients who underwent GI tumor resections may additionally require anticancer therapy after 
surgery. Investigating the impact of GI surgery on the bioavailability of antitumoral drugs is therefore 
vital. 
4.7.1. Tegafur 
Two controlled studies demonstrated that the systemic exposure to oral tegafur after gastrectomy (n 
= 26 and n = 12) was comparable to that before surgery 59,60, indicating that gastrectomy has no 
impact on the bioavailability of this drug. 
4.7.2. Imatinib 
Oral administration of imatinib in patients with an anatomically changed GI tract seemed to result in 
a reduced bioavailability. In one patient with BPD with duodenal switch, plasma through levels were 
measured before and after surgery and a 83% reduction was observed postoperatively, resulting in 
inadequate levels.62 Additionally, the trough concentrations of imatinib after gastric bypass surgery 
were also reduced, although treatment with imatinib was successful in this one patient.61  
4.7.3. Temozolomide  
One case report described the failure of oral therapy with temozolomide in a patient who had 
previously undergone gastric bypass surgery.63 Temozolomide plasma concentrations were measured 
in order to explain this inadequate therapy, but these plasma levels were consistent with values 
reported for patients with a normal GI tract, indicating that failure of therapy was not due to an 
anatomically changed GI tract. 
 
4 CONCLUSION 
Although many studies have examined the impact of an anatomically changed GI tract on the oral 
bioavailability of drugs, this review confirms that this impact is drug-specific and complicated by 
many factors. Not unexpectedly, the effect of GI surgery on the bioavailability was independent from 
the pharmacological properties of the drugs studied.  
Since solubility and permeability of a drug are important factors that determine the rate and extent 
of drug absorption, using the Biopharmaceutical Classification System could provide a better insight 
in the influence of GI surgery on the absorption and, consequently, on the oral bioavailability of 
drugs. However, it turns out that the impact on absorption is not biopharmaceutical class-specific. 
Many other factors such as active transporter mechanisms and first pass metabolism should be taken 
into account when drug absorption and oral bioavailability are studied. Classifying the drugs 
according to the Biopharmaceutical Drug Disposition Classification System could therefore be useful 
as a first tool to estimate the risk of changed drug absorption and/or bioavailability after GI surgery. 
Although this classification system was not developed to predict drug absorption and/or 
bioavailability, this system incorporates elimination routes, transporter-effects, transporter-enzyme 
interplay and post absorption transporter effects.74 Unfortunately, our efforts to classify the drugs 
according to this system have not revealed any class-specific effects as a result of the different GI 
surgical procedures.  
One could argue that, for some drugs, the available evidence for an altered bioavailability after GI 
surgery is restricted to case reports and small sample size studies. In addition, some of the discussed 
surgical procedures (e.g. vagotomy, JIB, BPD) are nowadays less performed or even largely outdated. 
Nevertheless, these surgical procedures as well as case reports could provide interesting information 
and are indicative for further research or for other types of GI surgery. 
In conclusion, the impact of an anatomically changed GI tract on the oral bioavailability of drugs is an 
individual drug related matter. Further research to examine this impact is required for each drug 
separately. In order to investigate the impact of a purely anatomically changed GI tract, the choice of 
appropriate controls as comparison group seems to be vital for the interpretation of the results. The 
control group should have the same characteristics such as bodyweight, sex and medical condition 
(healthy or treated for the same disease) as the test group. Therefore, studying the same subjects 
before and after intervention seems to be the most ideal situation. 
This review focused on the impact of an anatomically changed GI tract on the bioavailability of drugs, 
and not on efficacy. Even though there is a good correlation between systemic exposure and efficacy 
for most drugs, a reduced bioavailability does not necessarily result in an inadequate therapy. 
Nevertheless, evaluating the bioavailability of oral drugs in patients with an anatomically changed GI 
tract may be a first step in estimating the risk of unsuccessful therapy in this patient population. 
Academic centers, investigators and grant-funding bodies should address these complications in 
order to assist clinicians by presenting guidelines for oral drug dosing in this specific patient 
population. 
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